img

Global Pneumococcal Vaccine Polyvalent Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pneumococcal Vaccine Polyvalent Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Pneumococcal vaccines are vaccines against the bacteria Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis.
The global Pneumococcal Vaccine Polyvalent market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Pneumococcal Vaccine Polyvalent is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Pneumococcal Vaccine Polyvalent include Merck & Co. and Pfizer etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Pneumococcal Vaccine Polyvalent, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Pneumococcal Vaccine Polyvalent by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Pneumococcal Vaccine Polyvalent market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pneumococcal Vaccine Polyvalent market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Merck & Co.
Pfizer
By Type
Prevnar 13
Pneumovax23
By Application
18 Years and Younger
19 To 64 Years Old
65 Years and Older
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pneumococcal Vaccine Polyvalent in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pneumococcal Vaccine Polyvalent manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Vaccine Polyvalent sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pneumococcal Vaccine Polyvalent Definition
1.2 Market by Type
1.2.1 Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Prevnar 13
1.2.3 Pneumovax23
1.3 Market Segment by Application
1.3.1 Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 18 Years and Younger
1.3.3 19 To 64 Years Old
1.3.4 65 Years and Older
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pneumococcal Vaccine Polyvalent Sales
2.1 Global Pneumococcal Vaccine Polyvalent Revenue Estimates and Forecasts 2018-2034
2.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Pneumococcal Vaccine Polyvalent Revenue by Region
2.3.1 Global Pneumococcal Vaccine Polyvalent Revenue by Region (2018-2023)
2.3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Region (2024-2034)
2.4 Global Pneumococcal Vaccine Polyvalent Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Region
2.6.1 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Region (2018-2023)
2.6.2 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Manufacturers
3.1.1 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Pneumococcal Vaccine Polyvalent Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Pneumococcal Vaccine Polyvalent Sales in 2024
3.2 Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers
3.2.1 Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers (2018-2023)
3.2.2 Global Pneumococcal Vaccine Polyvalent Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Pneumococcal Vaccine Polyvalent Revenue in 2024
3.3 Global Pneumococcal Vaccine Polyvalent Sales Price by Manufacturers
3.4 Global Key Players of Pneumococcal Vaccine Polyvalent, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pneumococcal Vaccine Polyvalent Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Product Offered and Application
3.8 Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Type
4.1.1 Global Pneumococcal Vaccine Polyvalent Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Pneumococcal Vaccine Polyvalent Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pneumococcal Vaccine Polyvalent Revenue by Type
4.2.1 Global Pneumococcal Vaccine Polyvalent Historical Revenue by Type (2018-2023)
4.2.2 Global Pneumococcal Vaccine Polyvalent Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
4.3 Global Pneumococcal Vaccine Polyvalent Price by Type
4.3.1 Global Pneumococcal Vaccine Polyvalent Price by Type (2018-2023)
4.3.2 Global Pneumococcal Vaccine Polyvalent Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pneumococcal Vaccine Polyvalent Sales Quantity by Application
5.1.1 Global Pneumococcal Vaccine Polyvalent Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Pneumococcal Vaccine Polyvalent Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pneumococcal Vaccine Polyvalent Revenue by Application
5.2.1 Global Pneumococcal Vaccine Polyvalent Historical Revenue by Application (2018-2023)
5.2.2 Global Pneumococcal Vaccine Polyvalent Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
5.3 Global Pneumococcal Vaccine Polyvalent Price by Application
5.3.1 Global Pneumococcal Vaccine Polyvalent Price by Application (2018-2023)
5.3.2 Global Pneumococcal Vaccine Polyvalent Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pneumococcal Vaccine Polyvalent Sales by Company
6.1.1 North America Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023)
6.1.2 North America Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023)
6.2 North America Pneumococcal Vaccine Polyvalent Market Size by Type
6.2.1 North America Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2034)
6.2.2 North America Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2034)
6.3 North America Pneumococcal Vaccine Polyvalent Market Size by Application
6.3.1 North America Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2034)
6.3.2 North America Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2034)
6.4 North America Pneumococcal Vaccine Polyvalent Market Size by Country
6.4.1 North America Pneumococcal Vaccine Polyvalent Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Pneumococcal Vaccine Polyvalent Revenue by Country (2018-2034)
6.4.3 North America Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pneumococcal Vaccine Polyvalent Sales by Company
7.1.1 Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023)
7.1.2 Europe Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023)
7.2 Europe Pneumococcal Vaccine Polyvalent Market Size by Type
7.2.1 Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2034)
7.2.2 Europe Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2034)
7.3 Europe Pneumococcal Vaccine Polyvalent Market Size by Application
7.3.1 Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2034)
7.3.2 Europe Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2034)
7.4 Europe Pneumococcal Vaccine Polyvalent Market Size by Country
7.4.1 Europe Pneumococcal Vaccine Polyvalent Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2018-2034)
7.4.3 Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pneumococcal Vaccine Polyvalent Sales by Company
8.1.1 China Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023)
8.1.2 China Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023)
8.2 China Pneumococcal Vaccine Polyvalent Market Size by Type
8.2.1 China Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2034)
8.2.2 China Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2034)
8.3 China Pneumococcal Vaccine Polyvalent Market Size by Application
8.3.1 China Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2034)
8.3.2 China Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pneumococcal Vaccine Polyvalent Sales by Company
9.1.1 APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023)
9.1.2 APAC Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023)
9.2 APAC Pneumococcal Vaccine Polyvalent Market Size by Type
9.2.1 APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2034)
9.2.2 APAC Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2034)
9.3 APAC Pneumococcal Vaccine Polyvalent Market Size by Application
9.3.1 APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2034)
9.3.2 APAC Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2034)
9.4 APAC Pneumococcal Vaccine Polyvalent Market Size by Region
9.4.1 APAC Pneumococcal Vaccine Polyvalent Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Pneumococcal Vaccine Polyvalent Revenue by Region (2018-2034)
9.4.3 APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales by Company
10.1.1 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Market Size by Type
10.2.1 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Market Size by Application
10.3.1 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Market Size by Country
10.4.1 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Merck & Co.
11.1.1 Merck & Co. Company Information
11.1.2 Merck & Co. Overview
11.1.3 Merck & Co. Pneumococcal Vaccine Polyvalent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Merck & Co. Pneumococcal Vaccine Polyvalent Products and Services
11.1.5 Merck & Co. Pneumococcal Vaccine Polyvalent SWOT Analysis
11.1.6 Merck & Co. Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Pneumococcal Vaccine Polyvalent Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Pfizer Pneumococcal Vaccine Polyvalent Products and Services
11.2.5 Pfizer Pneumococcal Vaccine Polyvalent SWOT Analysis
11.2.6 Pfizer Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pneumococcal Vaccine Polyvalent Value Chain Analysis
12.2 Pneumococcal Vaccine Polyvalent Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pneumococcal Vaccine Polyvalent Production Mode & Process
12.4 Pneumococcal Vaccine Polyvalent Sales and Marketing
12.4.1 Pneumococcal Vaccine Polyvalent Sales Channels
12.4.2 Pneumococcal Vaccine Polyvalent Distributors
12.5 Pneumococcal Vaccine Polyvalent Customers
13 Market Dynamics
13.1 Pneumococcal Vaccine Polyvalent Industry Trends
13.2 Pneumococcal Vaccine Polyvalent Market Drivers
13.3 Pneumococcal Vaccine Polyvalent Market Challenges
13.4 Pneumococcal Vaccine Polyvalent Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Prevnar 13
Table 3. Major Manufacturers of Pneumovax23
Table 4. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Pneumococcal Vaccine Polyvalent Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Pneumococcal Vaccine Polyvalent Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2018-2023)
Table 8. Global Pneumococcal Vaccine Polyvalent Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region (2024-2034)
Table 10. Global Pneumococcal Vaccine Polyvalent Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 11. Global Pneumococcal Vaccine Polyvalent Sales by Region (2018-2023) & (K Units)
Table 12. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2018-2023)
Table 13. Global Pneumococcal Vaccine Polyvalent Sales by Region (2024-2034) & (K Units)
Table 14. Global Pneumococcal Vaccine Polyvalent Sales Market Share by Region (2024-2034)
Table 15. Global Pneumococcal Vaccine Polyvalent Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 16. Global Pneumococcal Vaccine Polyvalent Sales Quantity Share by Manufacturers (2018-2023)
Table 17. Global Pneumococcal Vaccine Polyvalent Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Pneumococcal Vaccine Polyvalent Revenue Share by Manufacturers (2018-2023)
Table 19. Global Pneumococcal Vaccine Polyvalent Price by Manufacturers 2018-2023 (USD/Unit)
Table 20. Global Key Players of Pneumococcal Vaccine Polyvalent, Industry Ranking, 2021 VS 2024
Table 21. Global Pneumococcal Vaccine Polyvalent Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Pneumococcal Vaccine Polyvalent by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pneumococcal Vaccine Polyvalent as of 2024)
Table 23. Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Product Offered and Application
Table 25. Global Key Manufacturers of Pneumococcal Vaccine Polyvalent, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2023) & (K Units)
Table 28. Global Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Pneumococcal Vaccine Polyvalent Sales Quantity Share by Type (2018-2023)
Table 30. Global Pneumococcal Vaccine Polyvalent Sales Quantity Share by Type (2024-2034)
Table 31. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Pneumococcal Vaccine Polyvalent Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Pneumococcal Vaccine Polyvalent Revenue Share by Type (2018-2023)
Table 34. Global Pneumococcal Vaccine Polyvalent Revenue Share by Type (2024-2034)
Table 35. Pneumococcal Vaccine Polyvalent Price by Type (2018-2023) & (USD/Unit)
Table 36. Global Pneumococcal Vaccine Polyvalent Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2023) & (K Units)
Table 38. Global Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Pneumococcal Vaccine Polyvalent Sales Quantity Share by Application (2018-2023)
Table 40. Global Pneumococcal Vaccine Polyvalent Sales Quantity Share by Application (2024-2034)
Table 41. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Pneumococcal Vaccine Polyvalent Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Pneumococcal Vaccine Polyvalent Revenue Share by Application (2018-2023)
Table 44. Global Pneumococcal Vaccine Polyvalent Revenue Share by Application (2024-2034)
Table 45. Pneumococcal Vaccine Polyvalent Price by Application (2018-2023) & (USD/Unit)
Table 46. Global Pneumococcal Vaccine Polyvalent Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023) & (US$ Million)
Table 48. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023) & (K Units)
Table 49. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2023) & (K Units)
Table 50. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2023) & (US$ Million)
Table 52. North America Pneumococcal Vaccine Polyvalent Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2023) & (K Units)
Table 54. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2023) & (US$ Million)
Table 56. North America Pneumococcal Vaccine Polyvalent Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Pneumococcal Vaccine Polyvalent Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 58. North America Pneumococcal Vaccine Polyvalent Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Pneumococcal Vaccine Polyvalent Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2018-2023) & (K Units)
Table 61. North America Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023) & (K Units)
Table 63. Europe Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023) & (US$ Million)
Table 64. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2023) & (K Units)
Table 65. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2023) & (US$ Million)
Table 67. Europe Pneumococcal Vaccine Polyvalent Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2023) & (K Units)
Table 69. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2023) & (US$ Million)
Table 71. Europe Pneumococcal Vaccine Polyvalent Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Pneumococcal Vaccine Polyvalent Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 73. Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Pneumococcal Vaccine Polyvalent Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2018-2023) & (K Units)
Table 76. Europe Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023) & (K Units)
Table 78. China Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023) & (US$ Million)
Table 79. China Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2023) & (K Units)
Table 80. China Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2023) & (US$ Million)
Table 82. China Pneumococcal Vaccine Polyvalent Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2023) & (K Units)
Table 84. China Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2023) & (US$ Million)
Table 86. China Pneumococcal Vaccine Polyvalent Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023) & (K Units)
Table 88. APAC Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023) & (US$ Million)
Table 89. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2023) & (K Units)
Table 90. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2023) & (US$ Million)
Table 92. APAC Pneumococcal Vaccine Polyvalent Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2023) & (K Units)
Table 94. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2023) & (US$ Million)
Table 96. APAC Pneumococcal Vaccine Polyvalent Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Pneumococcal Vaccine Polyvalent Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 98. APAC Pneumococcal Vaccine Polyvalent Revenue by Region (2018-2023) & (US$ Million)
Table 99. APAC Pneumococcal Vaccine Polyvalent Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Region (2018-2023) & (K Units)
Table 101. APAC Pneumococcal Vaccine Polyvalent Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Company (2018-2023) & (K Units)
Table 103. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Company (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Type (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Application (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Country (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2018-2023) & (K Units)
Table 116. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Merck & Co. Company Information
Table 118. Merck & Co. Description and Overview
Table 119. Merck & Co. Pneumococcal Vaccine Polyvalent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 120. Merck & Co. Pneumococcal Vaccine Polyvalent Product and Services
Table 121. Merck & Co. Pneumococcal Vaccine Polyvalent SWOT Analysis
Table 122. Merck & Co. Recent Developments
Table 123. Pfizer Company Information
Table 124. Pfizer Description and Overview
Table 125. Pfizer Pneumococcal Vaccine Polyvalent Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 126. Pfizer Pneumococcal Vaccine Polyvalent Product and Services
Table 127. Pfizer Pneumococcal Vaccine Polyvalent SWOT Analysis
Table 128. Pfizer Recent Developments
Table 129. Key Raw Materials Lists
Table 130. Raw Materials Key Suppliers Lists
Table 131. Pneumococcal Vaccine Polyvalent Distributors List
Table 132. Pneumococcal Vaccine Polyvalent Customers List
Table 133. Pneumococcal Vaccine Polyvalent Market Trends
Table 134. Pneumococcal Vaccine Polyvalent Market Drivers
Table 135. Pneumococcal Vaccine Polyvalent Market Challenges
Table 136. Pneumococcal Vaccine Polyvalent Market Restraints
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Pneumococcal Vaccine Polyvalent Product Picture
Figure 2. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Pneumococcal Vaccine Polyvalent Market Share by Type in 2024 & 2034
Figure 4. Prevnar 13 Product Picture
Figure 5. Pneumovax23 Product Picture
Figure 6. Global Pneumococcal Vaccine Polyvalent Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Pneumococcal Vaccine Polyvalent Market Share by Application in 2024 & 2034
Figure 8. 18 Years and Younger
Figure 9. 19 To 64 Years Old
Figure 10. 65 Years and Older
Figure 11. Pneumococcal Vaccine Polyvalent Report Years Considered
Figure 12. Global Pneumococcal Vaccine Polyvalent Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Pneumococcal Vaccine Polyvalent Revenue 2018-2034 (US$ Million)
Figure 14. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 15. Global Pneumococcal Vaccine Polyvalent Sales Quantity 2018-2034 (K Units)
Figure 16. Global Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Region (2018-2023)
Figure 17. Global Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Pneumococcal Vaccine Polyvalent Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Pneumococcal Vaccine Polyvalent Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Pneumococcal Vaccine Polyvalent Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Pneumococcal Vaccine Polyvalent Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Pneumococcal Vaccine Polyvalent Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Pneumococcal Vaccine Polyvalent Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Pneumococcal Vaccine Polyvalent Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Pneumococcal Vaccine Polyvalent Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Pneumococcal Vaccine Polyvalent Sales Quantity in 2024
Figure 29. The Top 10 and Top 5 Players Market Share by Pneumococcal Vaccine Polyvalent Revenue in 2024
Figure 30. Pneumococcal Vaccine Polyvalent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 31. Global Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
Figure 33. Global Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
Figure 35. North America Pneumococcal Vaccine Polyvalent Revenue Market Share by Company in 2024
Figure 36. North America Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Company in 2024
Figure 37. North America Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
Figure 39. North America Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
Figure 41. North America Pneumococcal Vaccine Polyvalent Revenue Share by Country (2018-2034)
Figure 42. North America Pneumococcal Vaccine Polyvalent Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Company in 2024
Figure 46. Europe Pneumococcal Vaccine Polyvalent Revenue Market Share by Company in 2024
Figure 47. Europe Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
Figure 49. Europe Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
Figure 51. Europe Pneumococcal Vaccine Polyvalent Revenue Share by Country (2018-2034)
Figure 52. Europe Pneumococcal Vaccine Polyvalent Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 54. France Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 58. China Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Company in 2024
Figure 59. China Pneumococcal Vaccine Polyvalent Revenue Market Share by Company in 2024
Figure 60. China Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
Figure 62. China Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
Figure 64. APAC Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Company in 2024
Figure 65. APAC Pneumococcal Vaccine Polyvalent Revenue Market Share by Company in 2024
Figure 66. APAC Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
Figure 68. APAC Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
Figure 70. APAC Pneumococcal Vaccine Polyvalent Revenue Share by Region (2018-2034)
Figure 71. APAC Pneumococcal Vaccine Polyvalent Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 76. India Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Pneumococcal Vaccine Polyvalent Revenue Share by Country (2018-2034)
Figure 85. Brazil Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Pneumococcal Vaccine Polyvalent Revenue (2018-2034) & (US$ Million)
Figure 90. Pneumococcal Vaccine Polyvalent Value Chain
Figure 91. Pneumococcal Vaccine Polyvalent Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed